Trial Profile
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2015
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Isolated systolic hypertension
- Focus Therapeutic Use
- Acronyms ALIAS
- Sponsors Novartis
- 23 Aug 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
- 23 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2010 New trial record